Sign In
Buy IDRSF
$5.75
+0 (+0%)
At Close: Jun 02, 2026
Allschwil, Switzerland – June 1, 2026 Idorsia Ltd (SIX: IDIA) today announced additional positive clinical results for IDOR-1134-2831, its vaccine targeting Clostridioides difficile (C. difficile) i
Allschwil, Switzerland – June 01, 2026 Idorsia Ltd (SIX: IDIA) announces new analyses from the Phase 3 PRECISION study demonstrating that aprocitentan, Idorsia's dual endothelin receptor antagonist,
Shareholders vote in favor of all proposals by the Board at Idorsia's Annual General Meeting 2026
10:44am, Wednesday, 06'th May 2026
Allschwil, Switzerland – May 6, 2026 At today's Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted convincingly in favor of all proposals by the B
Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year
01:00am, Tuesday, 28'th Apr 2026
Ad hoc announcement pursuant to Art. 53 LR Preparation is underway to publish the strong pediatric daridorexant data and engage with regulatory authorities on next steps Co-promotion of QUVIVIQ is bei
Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders
01:00am, Friday, 10'th Apr 2026
Allschwil, Switzerland – April 10, 2026 Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meet
Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development
01:00am, Thursday, 09'th Apr 2026
Allschwil, Switzerland – April 9, 2026 Idorsia Ltd (SIX: IDIA) announces the appointment of Dr Amer Joseph as Executive Vice President, Chief Medical Officer (CMO) & Head of Global Clinical Developm
Idorsia Ltd (IDRSF) Discusses Positive Phase II Results for Daridorexant in Pediatric Insomnia and Neurodevelopmental Disorders Transcript
Idorsia announces the nomination of three candidates for election to the Board of Directors
02:00am, Tuesday, 24'th Mar 2026
Allschwil, Switzerland – March 24, 2026 Idorsia Ltd (SIX: IDIA) announces that the Board of Directors will propose three candidates for election to the Board at the upcoming Annual General Meeting o
Idorsia announces management change
02:00am, Monday, 16'th Mar 2026
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 16, 2026 Idorsia Ltd (SIX: IDIA) announces that Dr Srishti Gupta and the Board of Idorsia have mutually agreed that Srishti
Idorsia expands QUVIVIQ's global footprint through new partnership with Pharmalink
02:00am, Tuesday, 10'th Mar 2026
Allschwil, Switzerland – March 10, 2026 Idorsia Ltd (SIX: IDIA) has entered into an exclusive agreement with Pharmalink Drug Store L.L.C for the distribution and commercialization of QUVIVIQ™ (dar
Idorsia Ltd (IDRSF) Q4 2025 Earnings Call Transcript
02:17pm, Thursday, 26'th Feb 2026
Idorsia Ltd (IDRSF) Q4 2025 Earnings Call Transcript
Ad hoc announcement pursuant to Art. 53 LR Idorsia delivers on its upgraded 2025 guidance, with strong QUVIVIQ sales growth, disciplined investment, and a significantly improved bottom line.
Invitation to Idorsia's FY 2025 Financial Reporting webcast and conference call
11:45am, Thursday, 12'th Feb 2026
Idorsia will publish its Full Year 2025 Financial Reporting on Thursday February 26, at 07:00 CET. An investor webcast and conference call will be held to discuss the results on the same day.
Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium
01:00am, Friday, 30'th Jan 2026
Allschwil, Switzerland – January 30, 2026 Idorsia Ltd (SIX: IDIA) announces that the results of lucerastat treatment over 42-months and the kidney biopsy data will be presented at the 22nd Annual WO
Global expansion of Idorsia's QUVIVIQ continues with EMS partnership for Latin America
01:00am, Wednesday, 28'th Jan 2026
Ad hoc announcement pursuant to Art. 53 LR Regulatory dossier to obtain marketing authorization for QUVIVIQ has been submitted to ANVISA in Brazil Allschwil, Switzerland – January 28, 2026 Idorsia L
